Astra and Oxford Report Strong COVID-19 Vaccine
Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.
Following excellent data from Pfizer/BioNTech and Moderna, AstraZeneca (AZN) and partner Oxford reported favorable phase 3 data on COVID-19 vaccine AZD1222 with an efficacy rate of 90% (low dose) and 62% (full dose) with no major safety issues observed with the initial data cohort. At the low dose, the efficacy looks fairly similar to competitor data, albeit slightly lower than the 94%-95% efficacy reported by others. We are increasing the vaccine’s probability of approval to 90%, but given the firm’s commitment to pricing the vaccine at a non-profit level, we don’t expect any impact to Astra’s fair value estimate. However, the quick development of the vaccine reinforces the firm's innovative power and wide moat.
With the likely authorization of a third vaccine, we expect global demands will be more easily satisfied over the next few years. Astra expects manufacturing capacity of up to 3 billion doses in 2021. Combined with almost 2 billion doses in total from Pfizer/BioNTech’s and Moderna’s vaccines, close to 3 billion people could be vaccinated (assuming 1.5 to 2 doses for each person). Also, Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines, which may make Astra’s vaccine more appealing for less developed countries. Also, we expect additional pivotal data from Johnson & Johnson, Sanofi, GlaxoSmithKline and many more vaccine manufacturers in 2021. We continue to expect the pricing power of the vaccines to be low, especially with several competitors receiving government funding and stating a commitment to low vaccine pricing. However, we expect the very quick development of vaccines to enable the biopharma industry to gain goodwill with governments to help in discussions around any drug pricing reforms.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.